Nebulised ipratropium bromide and sodium cromoglycate in the first two years of life.

Publisher Website
Google Scholar
Abstract
In a double blind crossover trial, sodium cromoglycate, ipratropium bromide and water were compared in 23 asthmatic children < 2 yr old (mean age 11.8 mo). Each child received nebulized solutions containing 20 mg of sodium cromoglycate, 250 .mu.g of ipratropium bromide or 2 ml water 3 times a day for three 2 mo. periods. Daily symptom scores did not show significant differences between the treatments, but parental preferences indicated that both sodium cromoglycate and ipratropium bromide were superior to placebo. Sodium cromoglycate was prophylactic and was more likely to help the older patients. Ipratropium bromide produced an immediate clinical benefit and the response was not age-dependent. Responders were unable to be picked from non-responders on the basis of lung function tests performed on a routine outpatient basis. Both ipratropium bromide and sodium cromoglycate helped some but not all asthmatic children < 2 yr.